Combined lipid-lowering therapy in patients with nonalcoholic fatty liver disease

DOI: https://doi.org/10.29296/25877305-2018-11-07
Download full text PDF
Issue: 
11
Year: 
2018

P. Seliverstov, Candidate of Medical Sciences; S. Sitkin, Candidate of Medical Sciences; Professor V. Radchenko, MD; D. Tsurtsumia, Candidate of Medical Sciences; S. Dzhadzhav I.I. Mechnikov North-Western State Medical University, Saint Petersburg

The paper gives the results of an investigation evaluating the clinical efficacy of Chophytol (globe artichoke (Cynara scolymus) leaf extract) in patients with dyslipidemia. In patients with nonalcoholic fatty liver disease (NAFLD), the lipid profile has been noted to be normalized with Chophytol used alone and in combination with statins. In addition, the combined dyslipidemia correction regimen has contributed to the prevention of NAFLD progression with lipid profile normalization using low-dose statins.
Keywords: 
hepatology
therapy
nonalcoholic fatty liver disease
dyslipidemia
globe artichoke (Cynara scolymus) leaf extract
statins
Chophytol

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Lazebnik L.B. i dr. Nealkogol'naja zhirovaja bolezn' pecheni: klinika, diagnostika, lechenie (rekomendatsii dlja terapevtov, 2-ja versija) // Eksperim. i klin. gastroenterol. – 2017; 138 (2): 22–37.
  2. Ermolova T.V., Ermolov S.Ju., Beljaeva E.L. Nealkogol'naja zhirovaja bolezn' pecheni: sovremennyj vzgljad na problemu // Effektivnaja farmakoter. – 2016; 37: 26–35.
  3. Niederau C. NAFLD and NASH. Hepatology: clinical textbook. Ed. S. Mauss, T. Berg, J. Rockstroh et al. 2015.
  4. Leuschner U., James O., Dancygier H. Steatohepatitis. NASH and ASH / Springer, 2004; r. 35.
  5. Zheng L., Lv G., Sheng J. et al. Effect of miRNA–10b in regulating cellular steatosis level by targeting PPAR–alpha expression, a novel mechanism for the pathogenesis of NAFLD // J. Gastroenterol. Hepatol. – 2010; 25: 156–63.
  6. Drapkina O.M., Deeva T.A., Volkova N.P. i dr. Sovremennye podhody k diagnostike i lecheniju nealkogol'noj zhirovoj bolezni pecheni // Ter. arh. – 2014; 10: 116–23.
  7. Truhan D.I., Ivanova D.S. Nealkogol'naja zhirovaja bolezn' pecheni, assotsiirovannaja s ozhireniem: terapevticheskie vozmozhnosti // Consilium Medicum. – 2016; 18 (8): 54–60.
  8. Mehtieva S.N., Mehtieva O.A. Sovremennyj vzgljad na perspektivy terapii nealkogol'noj zhirovoj bolezni pecheni // Effektivnaja farmakoter. – 2011; 2: 50–7.
  9. Balukova E.V., Baryshnikova N.V., Belousova L.N. Nealkogol'naja zhirovaja bolezn' pecheni: sovremennoe sostojanie problemy // Farmateka. – 2016; 2: 63–8.
  10. Clark J. The epidemiology of nonalcoholic fatty liver disease in adults // J. Clin. Gastroenterol. – 2006; 40: 5–10.
  11. Mishra A., Younossi Z. Epidemiology and natural history of nonalcoholic fatty liver disease // J. Clin. Exp. Hepatol. – 2012; 2: 135–44.
  12. Welsh J., Karpen S., Vos M. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010 // J. Pediatrics. – 2013; 162 (3): 496–500.
  13. Younossi Z., Stepanova M., Affendy M. et al. Izmenenie rasprostranennosti osnovnyh hronicheskih boleznej pecheni v SShA s 1998 po 2008 god // Klin. gastroenterol., gepatol. – 2011; 5: 261–7.
  14. Ivashkin V.T., Drapkina O.M., Maev I.V. i dr. Rasprostranennost' nealkogol'noj zhirovoj bolezni pecheni u patsientov ambulatorno-poliklinicheskoj praktiki v Rossijskoj Federatsii: rezul'taty issledovanija DIREG 2 // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2015; 6: 31–41.
  15. Dam-Larsen S., Becker U., Franzmann M. et al. Final results of a long-term, clinical follow-up in fatty liver patients // Scand. J. Gastroenterol. – 2009; 44 (10): 1236–43.
  16. Drapkina O.M., Ivashkin V.T. Epidemiologicheskie osobennosti nealkogol'noj zhirovoj bolezni pecheni v Rossii (rezul'taty otkrytogo mnogotsentrovogo prospektivnogo issledovanija nabljudenija DIREGL 01903) // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2014; 24 (4): 32–8.
  17. Yoshitaka H., Hamaguchi M., Kojima T. et al. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease. A post hoc analysis of a cohort study // Medicine. – 2017; 96: 18.
  18. Byrne C. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease // Proc. Nutr. Soc. – 2013; 72: 412–9.
  19. Mahabadi A., Berg M., Lehmann N. et al. Association of epicardial fat with cardiovascular risk factors and incidentmyocardial infarction in the general population: the Heinz Nixdorf Recall Study // J. Am. Coll. Cardiol. – 2013; 61: 1388–95.
  20. Hamaguchi M., Kojima T., Takeda N. et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease // World J. Gastroenterol. – 2007; 13: 1579–84.
  21. Oganov R.G., Aronov D.M., Bubnova M.G. Primenenie statinov – paradigma profilaktiki i lechenija ateroskleroticheskih zabolevanij (fokus na atorvastatin) // Kardiovask. ter. i profilakt. – 2006; 5 (6): 95–107.
  22. Podymova S.D. Bolezni pecheni / M.: Meditsina, 2005; 768 s.
  23. Rukovodstvo po aterosklerozu i ishemicheskoj bolezni serdtsa. Pod red. E.I. Chazova, V.V. Kuharchuka, S.A. Bojtsova / M.: Media Medika, 2007.
  24. Tkachenko E.I., Suvorov A.N. Disbioz kishechnika. Rukovodstvo po diagnostike i lecheniju / SPb: SpetsLit, 2007; 238 s.
  25. Wigg A., Roberts-Thomson I., Dymock R. et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis // Gut. – 2001; 48 (2): 206–11.
  26. Karnejro de Mura M. Nealkogol'nyj steatogepatit // Klin. perspektivy v gastroenterol., gepatol. – 2001; 3: 12–5.
  27. Burt A., Mutton A., Day C. Diagnosis and interpretation of steatosis and steatohepatitis // Semin. Diagh. Pathol. – 1998; 15 (4): 246–58.
  28. Cherbut C., Aube A., Blottiere H. et al. Effects of short-chain fatty acids on gastrointestinal motility // Scand. J. Gastroenterol. – 1997; Suppl. 222: 58–61.
  29. Diagnostika i korrektsija narushenij lipidnogo obmena s tsel'ju profilaktiki i lechenija ateroskleroza. Rekomendatsii. VNOK // Kardiovask. ter. i profilakt. – 2007; 6 (6): Pril. 3.
  30. Kardiologija. Natsional'noe rukovodstvo. Pod red. Ju.N. Belenkova, R.G. Oganova / M.: GEOTAR-Media, 2007; 416 s.
  31. Aronov D.M. Lechenie ateroskleroticheskoj dislipidemii i ateroskleroza // Trudnyj patsient. – 2003; 1 (4): 31–4.
  32. Klimov A.N., Nikul'cheva N.P. Lipidy, lipoproteidy i ateroskleroz / SPb: Piter Press, 1995.
  33. Aronov D.M. Lechenie ateroskleroticheskoj dislipidemii i ateroskleroza // Trudnyj patsient. – 2003; 1 (4): 31–4.
  34. Dzhanashija P.H., Nazarenko V.A., Nikolaenko S.A. Dislipoproteidemii: klinika, diagnostika, lechenie. Ucheb. posob. / M.: Izd-vo Ros. gos. med. un-ta, 2000.
  35. Scherbakova M.Ju. Dislipoproteidemii // Kardiologija. – 2000; 2: 4–7.
  36. Lazebnik L.B., Zvenigorodskaja L.A., Morozov I.A. i dr. Kliniko-morfologicheskie izmenenija pecheni pri aterogennoj dislipidemii i pri lechenii statinami // Ter. arh. – 2003; 8: 51–5.
  37. Podymova S.D. Zhirovoj gepatoz, nealkogol'nyj steatogepatit. Kliniko-morfologicheskie osobennosti. Prognoz. Lechenie // RMZh. – 2005; 7 (2): 61–5.
  38. Bogomolov P.O., Shul'pekova Ju.O. Steatoz pecheni i nealkogol'nyj steatogepatit. Bolezni pecheni i zhelchevyvodjaschih putej. Izd. 2-e. Pod red. V.T. Ivashkina / 2005; s. 205–16.
  39. Isakov V.A. Statiny i pechen': druz'ja ili vragi? // Klin. gastroenterol. i gepatol.– 2008; 1 (5): 372–4.
  40. Lazebnik L.B., Zvenigorodskaja L.A. Metabolicheskij sindrom i organy pischevarenija / M.: Anaharsis, 2009; 184 s.
  41. Dixon J., Bhathal P., O’Brien P. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese // Gastroenterology. – 2001; 121 (1): 91–100.
  42. Shipulin V.P., Dolzhenko M.N. Hronicheskij steatogepatoz: prospektivnoe issledovanie funktsional'nogo sostojanija serdechno-sosudistoj sistemy // Krym. med. zhurn. – 2006; 3: 12–6.
  43. Drapkina O.M., Ivashkin V.T. Epidemiologicheskie osobennosti nealkogol'noj zhirovoj bolezni pecheni v Rossii (rezul'taty otkrytogo mnogotsentrovogo prospektivnogo issledovanija-nabljudenija DIREGL 01903) // Ros.zhurn. gastroenterol., gepatol., koloproktol. – 2014; 24 (4): 32–8.
  44. Drapkina O.M., Korneeva O.N. Nealkogol'naja zhirovaja bolezn' pecheni i serdechno-sosudistyj risk: vlijanie zhenskogo pola // Farmateka. – 2010; 15: 28–33.
  45. Mel'nikova N.V., Zvenigorodskaja L.A., Homeriki S.G. i dr. Metody korrektsii aterogennoj dislipidemii u bol'nyh nealkogol'nym steatogepatitom // RMZh. Bolezni organov pischevarenija. – 2006; 8 (2): 69–73.
  46. Savel'ev V.S., Petuhov V.A., Karalkin A.V. i dr. Vnepechenochnye biliarnye disfunktsii pri lipidnom distress-sindrome: etiopatogenez, diagnostika i printsipy lechenija // RMZh. – 2002; 9: 56–62.
  47. Anfossi G., Massucco P., Bonomo K. et al. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance be-tween risks and benefits // Nutr. Metab. Cardiovasc. Dis. – 2004; 14: 215–24.
  48. Argo C., Loria P., Caldwell S. et al. Statins in liver disease: a molehill, an iceberg, or neither? // Hepatology. – 2008; 48 (2): 662–9.
  49. Cohen L. Equallypotent inhibitors of cholesterol synthesis in human hepatocytes have distinquishable effects on different cytochrome P 450 enzymes / L.H. Cohen, R.E. van Leeuwen, G.C. van Thiel // Biopharm. Drug Dispos. – 2000; 21: 353–64.
  50. Souza O., Tadeu S., Cavaleiro A. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease // J. Gastroenterol. Hepatol. – 2010; 25: 357–61.
  51. Gotto A. The case for over the counter statins // Am. J. Cardiol. – 2004; 94: 753–6.
  52. Parra J., Reddy K. Hepatotoxicity of hypolipidemic drugs // Clin. Liver Dis. – 2003; 7 (2): 415–33.
  53. Pasternak R., Smith S. ACC/AHA/NHLBI clinical advisory on the use and safety of statins // JACC. – 2002; 40: 567–72.
  54. De Denus S., Spinier S., Miller K. Statins and liver toxicity: a meta-analysis // Pharmacotherapy. – 2004; 24 (5): 584–91.
  55. Anfossi G., Massucco P., Bonomo K. et al. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance be-tween risks and benefits // Nutr. Metab. Cardiovasc. Dis. – 2004; 14: 215–24.
  56. Argo C., Loria P., Caldwell S. et al. Statins in liver disease: a molehill, an iceberg, or neither? // Hepatology. – 2008; 48 (2): 662–9.
  57. Cohen L., van Leeuwen R., van Thiel G. Equallypotent inhibitors of cholesterol synthesis in human hepatocytes have distinquishable effects on different cytochrome P 450 enzymes // Biopharm. Drug Dispos. – 2000; 21: 353–64.
  58. Souza O., Tadeu S., Cavaleiro A. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease // J. Gastroenterol. Hepatol. – 2010; 25: 357–61.
  59. Gotto A. The case for over the counter statins // Am. J. Cardiol. – 2004; 94: 753–6.
  60. Parra J., Reddy K. Hepatotoxicity of hypolipidemic drugs // Clin. Liver Dis. – 2003; 7 (2): 415–33.
  61. Pasternak R., Smith S. ACC/AHA/NHLBI clinical advisory on the use and safety of statins // JACC. – 2002; 40: 567–72.
  62. De Denus S., Spinier S., Miller K. Statins and liver toxicity: a meta-analysis // Pharmacotherapy. – 2004; 24 (5): 584–91.
  63. Lindor K., Kowdley R., Heathcote E. et al. Ursodeoxycholic acid for treatment of non-alcoholic steatohepatitis. Results of randomized trial // Hepatology. – 2004; 39: 770–8.
  64. Kucherjavyj Ju.A., Stukova N.Ju., Ahtaeva M.L. Hronicheskij gepatit, tsirroz pecheni i gepatotselljuljarnaja kartsinoma – zven'ja odnoj tsepi // Klin. perspektivy gastroenterol., gepatol. – 2012; 5: 3–12.
  65. Englisch W., Beckers C., Unkauf M. et al. Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia // Arzneimittelforschun. – 2000; 50: 3: 260–5.
  66. Safaa M., Hanaa A., Abdel F. et al. Cynarascolymus for relieving on nonalcoholic steatohepatitis induced in rat // Int. J. Pharmacy and Pharmaceutical Sci. – 2013; 5 (1): 57–66.
  67. Pittler M., Thompson C., Ernst E. Artichoke leaf extract for treating hypercholesterolaemia // Cochrane Database Syst. Rev. – 2009; 4: CD003335.
  68. Lu Y., Zhu Y., Zhang L. et al. Ilexgenin A enhances the effects of simvastatin on non-alcoholic fatty liver disease without changes in simvastatin pharmacokinetics // Chin. J. Nat. Med. – 2018; 16 (6): 436–45. DOI: 10.1016/S1875-5364(18)30077-3.